This article is more than 5 years old. Information may no longer be current.

DermTech reports record sales, high production rates in fourth quarter

DermTech announced record sales and processed volume of its Pigmented Lesion Assay samples for the fourth quarter of 2016, according to a press release.

The number of samples processed increased from 200 in the first quarter of the year to over 1,300 in the fourth quarter, an increase of 550%.

Other accomplishments in 2016 include the company doubling its clinical research products business, obtaining two new large multinational pharmaceutical customers, publishing two additional validation studies in peer-reviewed journals and securing $6.7 million in equity financing.

“The rapid commercial adoption of our PLA assay and research products is due to clinicians and pharmaceutical companies across the country seeing the value of our non-invasive gene expression tests,” John Dobak, MD, CEO and president of DermTech, said in the release. “We will [be] continuing to scale our sales force and laboratory in 2017 to meet this strong demand.”

Reference: www.dermtech.com